Leaflet TICAGRELOR SWYSSI 60mg film-coated tablets
Indicated for: prevention of atherothrombotic events
Route of administration: oral
Substance: ticagrelor (antiplatelet agent)
ATC: B01AC24 (Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin)
This medicine may have important interactions with other medicines.
This medicine may increase the risk of bleeding.
Ticagrelor is an antiplatelet medication used to prevent thrombotic events such as myocardial infarction or stroke in patients with acute coronary syndromes or a history of myocardial infarction. It works by reversibly inhibiting P2Y12 receptors on platelets, preventing platelet aggregation.
The medication is taken orally, usually twice daily, as directed by a doctor. It is important for patients to follow the prescribed dosage and not discontinue treatment without consulting their doctor.
Patients should be monitored for potential side effects, such as bleeding, shortness of breath, or dizziness. It is important to inform the doctor of any unusual symptoms or the use of other medications.
Common side effects include bleeding, shortness of breath, and dizziness. In rare cases, severe reactions such as major hemorrhages or bradycardia may occur. Patients should be informed of these risks before starting treatment.
General data about TICAGRELOR SWYSSI 60mg
- Substance: ticagrelor
- Date of latest medicines list: 01-05-2024
- Product code: W70208001
- Concentration: 60mg
- Pharmaceutical form: film-coated tablets
- Quantity: 1
- Product type: Generic medicine
- Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.
Concentrations available for ticagrelor
- 60mg
- 90mg